70
Participants
Start Date
December 9, 2022
Primary Completion Date
May 12, 2025
Study Completion Date
May 12, 2025
BMS-986360
Specified dose on specified days
Docetaxel
Specified dose on specified days
Nivolumab
Specified dose on specified days
Capecitabine
Specified dose on specified days
Local Institution - 0033, Ciudad Autónoma de Buenos Aires
Local Institution - 0031, Buenos Aires
Local Institution - 0010, Darlinghurst
Local Institution - 0061, St Leonards
Local Institution - 0063, Frankston
Local Institution - 0008, Brisbane
Local Institution - 0059, Candiolo
Local Institution - 0049, Marseille
Local Institution - 0057, Rozzano
Local Institution - 0055, Madrid
Local Institution - 0056, Madrid
Local Institution - 0018, Huntersville
Local Institution - 0050, Toulouse
Local Institution - 0065, Padua
Local Institution - 0028, Nashville
Local Institution - 0064, Seville
Local Institution - 0041, Zapopan
Local Institution - 0039, Monterrey
Local Institution - 0026, New Orleans
Local Institution - 0037, Puebla City
Local Institution - 0048, Paris
Local Institution - 0027, San Antonio
Local Institution - 0046, West Valley City
Local Institution - 0029, Los Angeles
Local Institution - 0051, Los Angeles
Local Institution - 0052, Villejuif
Local Institution - 0047, Santiago
Local Institution - 0035, Santiago
Local Institution - 0034, Santiago
Local Institution - 0001, Hackensack
Local Institution - 0030, CABA
Local Institution - 0003, Ottawa
Local Institution - 0005, Toronto
Local Institution - 0038, Mexico City
Local Institution - 0053, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY